tislelizumab
beigene,novartis
 new #immunotherapy option for #esophagealcancer rationale-306 just presented #wcgci2022 tislelizumab plus ctx mos 17.2 vs 10.6 in all comers mos 16.6 vs 10 in pdl&gt;10% orr 63.5 vs 42,2% 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine